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Abstract The assay of parathyroid hormone continues to
remain problematic as a result of the presence in the
circulation of a variety of parathyroid hormone (PTH)
peptides derived from secretion and from peripheral
metabolism. The detection of these PTH fragments to
varying degrees leads to widely differing results in the
various assays used, particularly in the setting of chronic
kidney disease, where PTH fragments accumulate as
glomerular filtration rate (GFR) falls. The differing results
not only lead to problems in comparing values from various
laboratories but also limit efforts to develop useful clinical
practice guidelines. At the same time, research into the
precise identification of the PTH fragments which contrib-
ute to the assay problems has uncovered a relatively new
area of parathyroid research that has pointed to potential
biologic activity of PTH peptides previously thought to be
biologically inactive and which may act on a novel PTH
receptor. These issues have brought new focus to the
difficulties in standardization of PTH assays and have
provoked efforts to provide standards to help in the
characterization of PTH assays and to facilitate the
development of clinical practice guidelines.
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Assay of parathyroid hormone is extremely important in
clinical medicine because of the major role of parathyroid
hormone in the regulation of mineral metabolism and
skeletal physiology. Since the introduction of radioimmu-
noassay for parathyroid hormone (PTH) in 1963 by Berson
et al., the assay of parathyroid hormone has been
problematic and remains so to the present day [1]. The
initial assays used polyclonal antisera, raised against intact
parathyroid hormone, an 84 amino-acid peptide, which had
been purified from parathyroid glands. Assay specificity
varied considerably with different antisera and gave rise to
terms such as N-terminal assays, midregion assays, and C-
terminal PTH assays, according to the predominant speci-
ficity of the antisera used. While all of these assays had
some clinical utility, they also allowed the characterization
of the secretion and metabolism of PTH which revealed the
basis for the widely different results that were obtained with
different assays [2]. Thus, it was demonstrated that
circulating immunoreactive parathyroid hormone was a
mixture of the intact 84 amino-acid hormone peptide and
several smaller molecular weight peptide fragments that
were derived by secretion from the parathyroid gland as
well as generated by peripheral metabolism of PTH [3–6].
The PTH peptides reacted in various assays to various
degrees. Thus, the assay of parathyroid hormone was not
only complicated by the reaction of these various PTH
fragments in the particular assay used, but was also
complicated by the fact that many of these fragments
depended upon the kidney for their removal from the
circulation and, accordingly, accumulated to a high degree
in the setting of kidney disease [7]. While structure–
function studies of parathyroid hormone indicated that the
structural determinants for biologic activity resided within
the first 34 amino acids, assays directed towards this region
of PTH proved to be of limited value in clinical situations.
Paradoxically, it appeared that radioimmunoassays with
determinants towards the middle and C-terminal region of
the PTH molecule appeared to provide the best clinical
utility [2].
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A major breakthrough in PTH assay occurred with the
application of immunometric assay technology to the mea-
surement of PTH [8, 9]. With these PTH assays, PTH was
captured from serum using an antibody directed towards one
region of the PTH molecule (usually towards the C-terminal
region) and then detected with an antibody directed towards
the other end of the PTH molecule (usually within the N-
terminal 34 amino acids). Such two-site assays were
believed to measure intact PTH (thus, were called “intact”
PTH assays) and became widely utilized clinically and are
the main type of PTH assay used at the present time.
Detailed investigation over the past several years has
revealed, however, that such assays are not specific for
intact PTH but also detect a family of PTH peptides that are
truncated at the N-terminus, a major one of which is PTH (7-
84) [10, 11], as illustrated in Fig. 1. These findings not only
brought a new area of confusion to the field of parathyroid
hormone assay but also sparked further research, which has
revealed interesting and important findings.
Further refinements in assay technique, by utilizing
detection antibodies that had specificity for the first four
amino-acids of PTH, allowed the measurement of true PTH
(1-84) and facilitated detailed investigations of parathyroid
hormone assay and parathyroid hormone physiology [12].
Although such specific PTH (1-84) assays are not in
widespread clinical use today, they provided a tool for
detailed research on parathyroid physiology and parathy-
roid hormone assay. These findings led to a reinvestigation
for potential biologic activity in PTH fragments that were
truncated at the N-terminus of the PTH (1-84) molecule. By
the use of synthetic human PTH (7-84), it was demonstrat-
ed that some biological activity could be attributed to such
PTH fragments that differed in direction from that of intact
PTH (1-84) [13, 14]. Thus, while intact parathyroid
hormone administration elevated serum calcium, N-termi-
nally truncated PTH fragments such as human PTH 7-84,
administered to rats, appeared to lower serum calcium, and
when co-administered with human PTH (1-84), blunted the
calcemic response. Those observations brought new cre-
dence to the work of Murray and others from many years
before, which had originally suggested that some biologic
activity might be attributable to fragments of parathyroid
hormone [15].
These observations have expanded our knowledge of
parathyroid physiology, but, at the same time, they have
focused attention on some significant clinical problems.
One such problem is that even with current immunometric
assay techniques, there is considerable heterogeneity in
results obtained using different assays from different
manufacturers [16]. The widely different results obtained
likely stems from the variable recognition of PTH frag-
ments such as PTH (7-84) by the various assays used. An
additional problem which follows is the questions that
surround the development and application of practice
guidelines for appropriate therapeutic targets for the
desirable levels of parathyroid hormone with regard to the
control of hyperparathyroidism in the setting of chronic
kidney disease. Thus, a pressing clinical issue is how to
compare results from one laboratory with those of another,



























Fig. 1 Diagram of the multiple species of PTH peptides in the
circulation. The major forms are depicted by heavy lines. The gray
areas depict the regions of the PTH sequence that are detected by
various antibodies for first-generation and second-generation immu-
nometric assays and indicate the PTH peptides that would be detected
in each assay. The symbol ( ) depicts a PTH 1-84 peptide that is
likely post-translationally modified in a region that interferes with its
detection by first-generation immunometric assays
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On the other hand, these apparent problems in PTH assay
also lead to a number of opportunities that may help the field
move forward. First, the recognition of potential biologic
activity for N-terminally truncated PTH fragments provides a
stimulus to try and uncover and define the physiological
importance of the biological role for such PTH fragments in
humans. Some evidence in vitro and in animal experiments has
been developed to indicate the likely presence of a specific
receptor for such PTH fragments (C-PTH-R), and preliminary
data have suggested that such receptorsmight exist particularly
in cells of the osteocyte lineage, thereby opening a new field of
parathyroid biology [17–19]. These observations also provide
the opportunity to learn how such PTH fragments might
function in a milieu where many types of PTH fragments
exist and circulate, such as in chronic kidney disease, and,
thus, the opportunity exists to learn whether these PTH
fragments will have a spectrum of activities when they exist
alone or in combination. The C-PTH-R differs from the PTH
receptor (PTH-R1), which is responsible for the classical
actions of PTH. PTH fragments with a truncated N-terminus,
such as PTH 7-84, do not bind to the PTH-R1 [20].
An additional problem raised by these observations is
the difficulty in trying to standardize PTH assay results
from different laboratories or reagent suppliers using the
various techniques and to achieve precise characterization
of antisera used. This issue is not unique to the assay of
PTH but is also relevant to other peptide hormone assays,
such as the assay of growth hormone [21]. The provision of
accurate PTH standards that could be used worldwide
would be helpful in this regard. Similarly, interpretation of
results obtained at the present time might also be facilitated
by the provision of biological samples on a worldwide basis
that could aid in the general characterization of assays used
and help with clinical decision making, particularly in the
setting of chronic kidney disease. These observations also
provide the stimulus and opportunity to revisit the use of
parathyroid hormone assay as a bone marker for the
management of renal osteodystrophy, and will likely lead
to a new era of bone biopsy to define correlations of
parathyroid hormone values and other biomarkers in the
current therapeutic era to try and facilitate clinical manage-
ment. To this point in time, intact PTH measurements have
been a relatively imprecise predictor of bone turnover [22–
24]. It has also been suggested that measurement of N-
terminally truncated PTH fragments such as PTH (7-84),
together with the values for PTH (1-84), might provide
useful information [25, 26]. This is an extremely contro-
versial area that requires much additional work to define the
biological role for PTH (7-84) in humans in a complex
milieu of other PTH fragments and to understand the
factors that may alter the relative amounts of PTH and
fragments, before clinical decision making should be based
upon such measurements [27–32].
In summary, problems with the assay of parathyroid
hormone continue but have uncovered new areas of
parathyroid hormone physiology and opened a new area
of investigation into potential biologic activity of PTH
fragments. As these assay problems are solved, and efforts
at standardization of PTH assays continue, it is likely that
we will be able to understand the total spectrum of biologic
activity of PTH and PTH fragments and incorporate the
information into clinical practice to improve the assessment
and management of abnormalities of mineral metabolism in
a variety of clinical circumstances.
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